Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort
Nicolas Dumonteil(Clinique Pasteur), Keith D. Dawkins(Boston Scientific (United States)), Thomas Modine(Université de Bordeaux), Jan Harnek(Getinge (Sweden)), Ian T. Meredith(The Alfred Hospital), Gilles Rioufol(Université Claude Bernard Lyon 1), Vicki M Houle(Boston Scientific (United States)), David Hildick‐Smith(Sussex County Community College), Nicolas M. Van Mieghem(Erasmus MC), D. Walters(Prince Charles Hospital), Didier Tchétché(Clinique Pasteur), Stephen G. Worthley(Royal Adelaide Hospital), Mark Spence(Mater Private Hospital), Thierry Lefèvre(Institut Cardiovasculaire Paris Sud), Daniel J. Blackman(Leeds Teaching Hospitals NHS Trust), Dominic J. Allocco(Boston Scientific (United States))
Cited by 30
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
|PubMed|2005|2.3k
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
|New England Journal of Medicine|2013|918
Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions
|Physiological Reviews|1990|792